Background The aim of this study was to compare the within-patient variability trough levels
(C o), dose-adjusted C o, and dose requirements of Prograf and Advograf with CYP3A5 …

Background Tacrolimus is a widely prescribed immunosuppressant agent for kidney
transplantation. However, optimal dosing is challenging due to its narrow therapeutic index …

Background and Objective The association between the CYP3A4* 1B single nucleotide
polymorphism (SNP) and tacrolimus pharmacokinetics in different studies is controversial …

Background: Selection of expected phenotypes (ie, expressers/non-expressers) is currently
used in CYP3A5* 3 genotype-based tacrolimus dosing. The authors assessed whether a …

Introduction: This study aimed to evaluate the effects of single nucleotide POLYMORPHISM
s CYP3A 4* 1B and CYP3A 5* 3 on TACROLIMUS dose requirement among kidney …

Aim: Tacrolimus is a substrate of CYP3A4 and CYP3A5. The present study investigated the
impact of the CYP3A4* 1/* 1G polymorphism compared with CYP3A5 genotypes on the …

Background: The aim of our study was to determine the impact of CYP3A5* 1 and CYP3A5*
3 on the kinetics of tacrolimus in renal transplant recipients. Material and methods: Forty …

Background Renal transplant is an effective treatment option for end-stage kidney disease
and tacrolimus is one of the most commonly used immunosuppressant drugs in renal …

What is known and objective Tacrolimus is a widely used immunosuppressive drug with
marked pharmacokinetic variability partly due to CYP 3A5 polymorphism. Our study aimed to …

Aim As a substrate of cytochrome P450 (CYP) 3A5, tacrolimus is characterised by a narrow
therapeutic index and large inter‐individual variability. Our objective was to determine the …